Phoenix, AZ October 30th – SmartPractice is announcing a distribution partnership change, effective January 1, 2024. The new partner, GHN Pharma, is based in Mölndal, Sweden and offers the marketing and logistics expertise needed to provide the market with the comprehensive line of SmartPractice products and the necessary education resources to aid clinicians in diagnosing patients.
SmartPractice is the worldwide leader in patch testing diagnostic products including: TRUE TEST® ready-to-use Patch Test, Finn Chamber®, allergEAZE® allergens and chambers, TruVol™ Precision Allergen Dispenser, patchProtect® and several other ancillary products. SmartPractice has global headquarters in Phoenix, AZ and additional manufacturing facilities in Hillerod, Denmark and Greven, Germany.
Visit our website for more information about SmartPractice patch test diagnostics www.smartpractice.com
“We are happy to have the team at GHN Pharma joining along side our team to ensure patients in the Scandinavian markets receive the diagnosis they deserve,” said Dr. Curt Hamann, CEO of SmartPractice. “The management team knows our products and will give the time and attention to the market to expand the availability of patch testing and the diagnosis of Allergic Contact Dermatitis.”
GHN Pharma Nordic AB is a ”Glocal” Speciality Pharma Company, with priority to original prescription medicines. The Strategy of GHN Pharma Nordic has two legs; Through its parent company, GHN Pharma International, GHN Pharma Nordic has access to international competence and a Global network. Through the local presence in the Nordic countries, GHN Pharma Nordic is able to incorporate a global outlook and combine this with local demands and requests. Through this strategy GHN Pharma Nordic establish partnerships with global partners for the benefit of the Nordic Health Care market. Visit our website www.ghnnordic.com
“Partnering with Smart Practise gives us the possibilities to widening our offers with quality products within competence areas Dermatology and Allergology, two of our prioritised areas.” said Tina Madsen Sandström, CEO GHN Pharma Nordic AB.
SmartPractice, Kristine Schreiber (moc.e1701704864citca1701704864rptra1701704864ms@re1701704864bierh1701704864csk1701704864)
GHN Pharma, Tina Madsen Sandstrøm (moc.a1701704864mrahp1701704864nhg@a1701704864nit1701704864)